Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
High body mass index (BMI) has been associated with an increased risk for breast cancer among postmenopausal women. However, the relationship between BMI and breast cancer risk in premenopausal women has remained unclear. Data from two large prevention trials conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) were used to explore the relationship between baseline BMI and breast cancer risk. The analyses included 12,243 participants with 253 invasive breast cancer events from the Breast Cancer Prevention Trial (P-1) and 19,488 participants with 557 events from the Study of Tamoxifen and Raloxifene (STAR). Both studies enrolled high-risk women (Gail score ≥ 1.66) with no breast cancer history. Women in P-1 were pre- and postmenopausal, whereas women in STAR (P-2) were all postmenopausal at entry. Using Cox proportional hazards regression, we found slight but nonsignificant increased risks of invasive breast cancer among overweight and obese postmenopausal participants in STAR and P-1. Among premenopausal participants, an increased risk of invasive breast cancer was significantly associated with higher BMI (P = 0.01). Compared with BMI less than 25, adjusted HRs for premenopausal women were 1.59 for BMI 25 to 29.9 and 1.70 for BMI 30 or more. Our investigation among annually screened, high-risk participants in randomized, breast cancer chemoprevention trials showed that higher levels of BMI were significantly associated with increased breast cancer risk in premenopausal women older than 35 years, but not postmenopausal women.
National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Center, One Sterling Plaza, 201 N Craig St., Suite 350, Pittsburgh, PA 15213, USA. cecchini@nsabp.pitt.edu
Reena S
RS
Cecchini
Joseph P
JP
Costantino
Jane A
JA
Cauley
Walter M
WM
Cronin
D Lawrence
DL
Wickerham
Stephanie R
SR
Land
Joel L
JL
Weissfeld
Norman
N
Wolmark
D000328:Adult; D000368:Aged; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009765:Obesity / Q000150:complications; D017698:Postmenopause; D017697:Premenopause; D016016:Proportional Hazards Models; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013629:Tamoxifen / Q000494:pharmacology
D013629:Tamoxifen; D020849:Raloxifene Hydrochloride